STAT+: The long wait for Cel-Sci to finally admit its cancer drug doesn’t work
Eventually, Cel-Sci will have to disclose the results of its Phase 3 cancer clinical trial. When that happens is anyone’s guess.
Tuesday marked one year since the small biotech announced the completion of the study, which is investigating an immune-boosting drug called Multikine in patients with head and neck cancer. There is no set timeline for how long it takes to analyze and read out results from a clinical trial, but generally, six weeks to two months is a good rule; allowing three or four months to crunch the numbers is being generous.
Continue to STAT+ to read the full story…
